A team led by the University of British Columbia homed in on a variant that linked to increased liver enzyme levels and liver injury during interferon-β treatment.
The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.
CBS New York reports that pharmacogenomic testing can explain why some patients do not get relief from certain treatments.
The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.
A Veterans Health Administration subcommittee evaluated the clinical utility of 30 pharmacogenetic tests and recommended about half for wider use.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
The CATCH-KB database is a standardized variant repository meant to support new research into prevention of chemotherapy-induced cardiotoxicity.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.